Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD ...

Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in ...

GSK’s up-to-$750M Chimagen trispecific T-cell engager for myeloma and Sanofi’s transfer of 20 mature drugs/three sites to ...

In a conversation with Pharmaceutical Executive, former U.S. Representative Joe Cunningham (D-SC), and spokesperson for the Pharmaceutical Reform Alliance, discussed the limitations of the new ...

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.

EVERSANA's Alan Crowther on why MFN's three programs, compounding interactions with IRA and 340B, and leverage gaps make it pharma's most consequential pricing challenge.

Deal economics for Orbis include >$1.4B upfront and milestones, tiered royalties, and a strategic Novo equity investment, ...

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon ...

Regulatory action establishes finerenone as the only non-steroidal MRA indicated for CKD with either type 1 or type 2 diabetes. Fine-One randomized adults with T1D-CKD to finerenone 10/20 mg daily vs ...

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, ...

Novo Nordisk and Anthropic will co-develop AI solutions for defined discovery bottlenecks, focusing on biological reasoning, scientific workflows, and accelerating progression from research insights ...